Erythrocyte membrane cholesterol/phospholipid chances and hemorheological modifications in familial hypercholesterolemia treated with lovastatin

Thrombosis Research

Volumn 83, Issue 5, 1996, Pages 375-388

  Martínez, Marcial ^a   Vayá, Amparo ^a   Martí, Roberto ^a   Gil, Lorenzo ^a   Lluch, Irene ^b   Carmena, Rafael ^b   Aznar, Justo ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Erythrocyte membrane lipids; Familial hypercholesterolemia; Hemorheology; Lovastatin

Indexed keywords

CHOLESTEROL; MEVINOLIN; PHOSPHOLIPID;

ADULT; AGED; ARTICLE; BLOOD RHEOLOGY; CLINICAL ARTICLE; ERYTHROCYTE MEMBRANE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030248472     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-3848(96)00147-8     Document Type: Article

References (75)

1. 1. FUSTER, V., BADIMON, L., BADIMON, J.J., CHESEBRO, J.H. The pathogenesis of coronary artery disease and the coronary syndromes. N Engl J Med 62, 242-250, 1992.
2. 2. ROSS, R. The pathogenesis of atherosclerosis. An update. New Engl J Med 314, 488-500, 1988.
3. 3. HOLME, I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease indice. Circulation 82, 1916-1924, 1990.
4. 4. COOPER, R.A. Abnormalities of cell-membrane fluidity in the pathogenesis of disease. N Engl J Med 297, 371-377, 1977.
5. 5. GOTTLIEB, M.H. Rates of cholesterol exchange between human erythrocytes and plasma lipoproteins. Biochem Biophys Acta, 600, 530-541, 1980.
6. 6. SCHICK, B.P., SCHICK, PK. Cholesterol exchange in platelets, erythrocytes and megakaryocytes. Biochem Biophys Acta 833, 281-290, 1985.
7. 7. VAYA, A., MARTINEZ, M., CARMENA, R., AZNAR, J. The lipid composition of red blood cells and their hemorheological behavior in patients with primary hyperlipoproteinemia. Clin Hemorheol 13, 447-457, 1993.
8. 8. ASHWART, L.A.E., GREEN, C. The transfer of alfa-lipoprotein and erythrocytes. Biochim Biophys Acta 84, 182-188, 1964.
9. 9. CHABANEL, A., FLAMM, M., SUNG, L.P., et al. Influence of cholesterol content on red cell membrane viscoelasticity and fluidity. Biophys J 44, 171-176, 1983.
10. 10. CHAP, H., DOUSTE-BLAZY, L. Membranes cellulaires et phospholipides. Arch Mal Coeur 78, 13-17, 1985.
11. 11. HANSS, M., KOUTSOURIS, D. The role of membrane lipids in erythrocyte rheology. Colloids Surface 14, 261, 1985.
12. 12. VAN BLITTERSWIJL, W.J., VAN DER MEER, B., HILKMAN, H. Quantitative contributions of cholesterol and the individual classes of phospholipids and their degree of fatty acyl (un)-saturation to membrane fluidity measured by fluorescence polarization. Biochemistry 26, 1746-1750, 1987.
13. 13. KANAKARAJ, P., SINGH, M. Influence of hypercholesterolemia on morphological and rheological characteristics of erythrocytes. Atherosclerosis 76, 209-218, 1989.
14. 14. MARTINEZ, M., VAYA, A., MOLINA, R., ANDRES, C., PEREZ-AGUILAR F., AZNAR, J. Alteraciones hemorreológicas en el paciente hepático. Relación con la morfología y la composición lipídica de la membrana eritrocitaria. Rev Iberoamer Tromb Hemostasis 3, 101-105, 1990.
15. 15. KOENIG, W., ERNST, E., MATRAI, A. Blood rheology associated with cardiovascular risk factors and chronic cardiovascular diseases: Results of an epidemiologic cross-sectional study. Angiology 38, 986-995, 1988.
16. 16. WILHELMSEN, L., SVARDSUDD, K., KORSAN-BENGTSEN, K., LARSSON, B., WELIN, L., TIBBLIN, G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311, 501-505, 1984.
17. 17. KANNEL, W.B., WOLF, P.A., CASTELLI, W.P., D'AGOSTINO, R.B. Fibrinogen and risk of cardiovascular disease: the Framingham study JAMA 258, 1183-1186, 1987.
18. 18. ERNST, E. Plasma fibrinogen-an independent cardiovascular risk factor. J Intern Med, 227, 365-372, 1990.
19. 19. HEINRICH, J., SCHULTE, H., BALLEISEN, L., ASSMAN, G., VAN de LOO, J. Predictive value of haemostatic variables in the PROCRAM study. Thromb Haemostas 65, 815, 1991.
20. 20. YARNELL, J.W., BAKER, I.A., SWEETNAM, P.M., BAINTON, D., O'BRIEN, J.R., WHITEHEAD, P.J., ELWOOD, P.C. Fibrinogen viscosity, and white cell count are major risk factors for ischemic heart disease. Circulation 83, 836-844, 1991.
21. 21. ERNST, E., RESCH, K.L. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 118, 956-963, 1993.
22. 22. LEE, A.J., LOWE, G.D.O., WOODWARD, M., TUNSTALL-PEDOE, H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary artery disease, and family history; the Scottish Heart Health Study. Br Heart J 69, 338-342, 1993.
23. 23. LOWE, G.D.O., FOWKES, F.G.R., DAWES, J., DONNAN, P.T., LENNIE, S.E., BIOL, M.I., HOUSELY, E. Blood viscosity, fibrinogen and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edimburg Artery Study. Circulation 87, 1915-1920, 1993.
24. 24. FOWKES, F.G.R., LOWE, G.D.O., HOUSLEY, E., RATTRAY, A., RUMLEY, A., ELTON, R.A., MAC GREGOR, I.R., DAWES, J. Cross linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 342, 84-86, 1993.
25. 25. CREMER, P., NAGEL, D., LABROT, B., MANN, H., MUCHE, R., ELSTER, H., SEIDEL, D. Lipoprotein Lp(a) as a predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen risk incidence and prevalence study. Eur J Clin Invest 24, 444-453, 1994.
26. 26. HEINRICH, J., BALLEISEN, L., SCHULTE, H., ASSMAN, G., VAN de LOO, J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb 14, 54-59, 1994.
27. 27. MEADE, T.W., BROZOVIC, M., CHAKRABARTI, R.R., HAINES, A.P., IMESON, J.D., MELLOWS, S., MILLER, G.J., NORTH, W.R.S., STIRLING, Y., THOMSON, S.G. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet ii, 533-537, 1986.
28. 28. STONE, M.C., THORP, J.M. Plasma fibrinogen-a major coronary risk factor. J Roy Coll Gen Prac 35, 565-569, 1984.
29. 29. CALOVERT, G.D., BLIGHT, L., FRANKLIN, J. The effect of clofibrate on plasma glucose, lipoproteins, fibrinogen and other biochemical and hematological variables in patients with mature onset diabetes mellitus. Eur J Clin Pharmacol 17, 355-362, 1980.
30. 30. CAIMI, G., FRANCAVILLA, G., ROMANO, A., CATANIA, A., SANTONOCITO, G., SARNO, A. Blood rheology changes during bezafibrate treatment. Brit J Clin Pract 42, 11-15, 1988.
31. 31. NIORT, G., BULGARELLI, A., CASSADER, M. et al. Effect of short term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. Atherosclerosis 71, 113-119, 1988.
32. 32. BO, M., BONINO, F., NEIROTTI, M., GOTTERO, M., PERNIGOTTI, L., MOLASCHI, M., FABRIS, F. Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs. Angiology 42, 106-113, 1991.
33. 33. MARTINEZ, M., VAYA, A., MICO, M.L., LLOPIS, I., BARBERA, J.L., AZNAR, J. Efecto de la simvastatina sobre las caracteristicas hemorreológicas de pacientes con hipercolesterolemia primaria. Rev Iberoamer Tromb Hemostasia 8, 20-23, 1995.
34. 34. LEVY, Y., LEIBOWITZ, R., AVIRAM, M., BROOK, J.G., COGAN, V. Reduction of plasma cholesterol by lovastatin normalizes erythrocyte membrane fluidity in patients with severe hypercholesterolemia. Br J Clin Pharmacol 34, 427-430, 1992.
35. 35. KOPPENSTEINER, R., MINAR, E., EHRINGER, H. Effect of lovastatin on hemorheology in type II hyperlipoproteinemia. Atherosclerosis 83, 53-58, 1990.
36. 36. BEIGEL, Y., FUCHS, J., SNIR, M., GREEN, P., LURIE, Y., DJALDETTI, M. Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorheologic parameters, platelet activity and red blood cell morphology. J Clin Pharmacol 31, 512-517, 1991.
37. 37. BEIGEL, Y., FUCHS, J., SNIR, M., LURIE, Y., GREEN, P., DJALDETTI, M. Lovastatin therapy in heterozygous familial hypercholesterolaemic patients: effect on blood rheology and fibrinogen levels. J Intern Med 230, 23-27, 1991.
38. 38. RAMSAY, L.E., YEO, W.W., JACKSON, P.R. Dietary reductions of serum cholesterol: time to tink again. BMJ 303, 953-957, 1991.
39. 39. CHISHOLM, A., MANN, J., SUTHERLAND, W., WILLIAMS, S., BALL, M. Dietary management of patients with familial hypercholesterolaemia treated with simvastatin. Q J Med 85, 825-831, 1992.
40. 40. BURSTEIN, M., SCHOLCNICK, H.R., MORFIN, R. Rapid method for isolation of lipoproteins from serum by precipitation with polyanions. J Lipid Res 11, 583, 1970.
41. 41. REID, H.L., BARNES, A.J., LOCK, P.J., DORMANDY, J.A., DORMANDY, J.L. A simple method for measuring erythrocyte deformability. Clin Pathol 9, 855-861, 1976.
42. 42. SCHMID-SCHONBEIN, H., VOLGER, E., TEITEL, P., KIESEWETTER, H., DAVER, V., HELLMANN, L. New hemorheological techniques for the routine laboratory. Clin Hemorheol 2, 93-105, 1982.
43. 43. DODGE, J.T., MITCHELL, C., HANAHAN, D.J. The preparation and chemical characteristics of hemoglobin free ghosts of human erythrocytes. Arch Biochem Biophys 100, 119-130, 1963.
44. 44. ROSE, H.G., OKLANDER, M. Improved procedure for the extraction from human erythrocytes. J Lipid Res 6, 128-131, 1965.
45. 45. ALLAIN, C.C., POON, L.S., CHAN, C.S.G., RICHMOND, W., FU, P.C. Enzymatic determination of total serum cholesterol. Clin Chem 20, 470-475, 1974.
46. 46. TAKAYAMA, M., ITOH, S., NAGASAKI, T., TAMINAZU, I. A new enzymatic method for determination of serum choline-containing phospholipids. Clin Chim Acta 79, 93-98, 1997.
47. 47. GRUNDY, S.M. HMGCoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 819, 24-33, 1988.
48. 48. TOBERT, J.A. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 62, 28J-33J, 1988.
49. 49. JIMENEZ, J., HERRERA, E., GUTIERREZ, J., MONTELONGO, A., LEON, B., MANTILLA, T., RUIZ, R., BARCINA, C. A multicenter study evaluating the effects of lovastatin on serum lipids in patients with hypercholesterolemia and high risk of coronary heart disease. Eur Heart J 11 Suppl 440, (Abstract), 1990.
50. 50. LETH, A., MUNCH, M., NIELSEN, B., DOLLERUP, J. Treatmen of severe primary hypercholesterolemia with lovastatin. A new therapeutic principle. Ugeskr Laeger 152, 3354-3357, 1990.
51. 51. MARTIN JADRAQUE, L., SANCHEZ, J., ROS, E., ESCOBAR, F., ASCASO, J., CABALLERO, M., NAVARRO, A., GONZALEZ, A., BERTOMEU, A., MICO, L., RUIZ, R. Treatment of primary hypercholesterolemia with lovastatin or bezafibrate. A multi center double-blind study. Eur Heart J 11 Suppl, 440 (Abstract), 1990.
52. 52. EBELING, T., TURTOIA, H., VOUTILAINEN, E., DUSITUPA, M., PYORALA, K., REIJONEN, T. Comparison between lovastatin and cholestyramine in the treatment of moderate to severe primary hypercholesterolemia. Ann Med 24, 121-127, 1992.
53. 53. FARMER, J.A., WASHINGTON, L., JONES, P.H., et al. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. Clin Ther 14, 708-717, 1992.
54. 54. ILLINGWORTH, D.R., BACON, S., PAPPU, A.S., SEXTON, G.J. Comparative hypolipemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 96, 63-64, 1992.
55. 55. MCPHERSON, R., BEDARD, J., CONNELLY, P., CURNEW, G., DAVIGNON, J., ECHENBERG, D., LAVIN, P., LEITER, L., LENIS, J., MC QUEEN, M. Comparison of the short-term efficacy and tolerabilityy of lovastatin and pravastatin in the management of primary hypercholesterolemia. Clin Ther 14, 276-291, 1992.
56. 56. SCHUMACHER, M., EBER, B., SILBERBAUER, K., BREIER, C., STUHLINGER, W., SCHMIDT, P., GAUL, G., KLEIN, W. Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia. Acta Med Austriaca 19, 140-144, 1992.
57. 57. VANHANEN, H., MIETTINEN, T.A. Pravastatin and lovastatin similary reduce serum cholesterol and its precursos levels in familial hypercholesterolemia. Eur J Clin Pharmacol 42, 127-130, 1192.
58. 58. FRONLICH, J., BRUN, L.D., BLANK, D, et al. Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia. Can J Cardiol 9, 405-412, 1993.
59. 59. HOCHGRAF, E., LEVY, Y., AVIRAM, M., BROOK, J.G., COGAN, U. Lovastatin decreases plasma and platelet cholesterol levels and normalizes elevated platelet fluidity and aggregation in hypercholesterolemic patients. Metabolism 43, 11-17, 1994.
60. 60. BACKER, D.E.G., ROSSENEU, M., DESLYPERE, J.P. Discriminative value of lipids and apolipoproteins in coronary heart disease. Atherosclerosis 42, 197-303, 1982.
61. 61. MULLER, S., ZIEGLER, O., DONNER, M., DROUIN, P., STOLTZ, J.F. Rheological properties and membrane fluidity of red blood cells and platelets in primary hyperlipoproteinemia. Atherosclerosis 83, 231-237, 1990.
62. 62. KUYPERS, F.A., ROELOFSEN, B., OP DEN KAMP, J.A.F., VAN DEENEN, L.L.M. The membrane of intact human erytrocyte tolerates only limited changes in the fatty acid composition of it phosphatidylcholine. Biochim Biophys Acta 769, 337-347, 1984.
63. 63. HAGVE, T.A., LIE, O., GRONN, M. The effect of dietary n-3 fatty acids on osmotic fragility and membrane fluidity of human erythrocytes. Scand J Clin Lab Invest 53 (Suppl 215), 75-84, 1993.
64. 64. BAUER, M., PLATT, D., HAGER, K. Effect of gemfibrozil on erythrocyte membrane lipids in geriatric patients. Exp Gerontol 25, 37-46, 1990.
65. 65. RABINI, R.A., POLENTA, M., STAFFOLANI, R., TOCCHINI, M., SIGNORE, R., TESTA, I., MAZZANTI, L. Effect of hydroxymethylglutaryl-CoA reductase inhibitors on the functional properties of erythrocyte membranes. Exp Mol Pathol 59, 51-57, 1993.
66. 66. BRANCHI, A., ROVELLINI, A., SOMMARIVA, D., GUGLIANDOLO, A.G., FASOLI, A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb-Haemost 70, 241-243, 1993.
67. 67. JAY, R.H., RAMPLING, M.W., BETTERIDGE, D.J. Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment. Atherosclerosis 85, 249-256, 1990.
68. 68. VAYA, A., MARTINEZ, M., CARMENA, R., AZNAR, J. Red blood cell aggregation and primary hyperlipoproteinemia. Thromb Res 72, 119-126, 1993.
69. 69. MARTINEZ, M., VAYA, A., GUINOT, M., AZNAR, J. Agregabilidad eritrocitaria en pacientes con riesgo cardiovascular. Influencia de los factures plasmáticos. Rev Iberoamer Tromb Hemostasia 4, 117-119, 1991.
70. 70. CHIEN, S., USAMI, S., DELLENBACK, R.J., GREGERSEN, M.I. Shear dependent interactions of plasma protein with erythrocytes in blood. Am J Physiol 219, 143-148, 1970.
71. 71. STOLTZ, J.F. Red cell aggregation. Clin Hemorheol 9, 693-884, 1989.
72. 72. STOLTZ, J.F., PAULUS, F., DONNER, M. Experimental approaches to erythrocyte aggregation. Clin Hemorheol 7, 33, 1987.
73. 73. STOLTZ, J.F., GAILLARD, S., ROUSSELLE, D., VOISIN, P., DROUIN, P. Rheological study of blood during primary hiperlipoproteinemia. Clin Hemorheol 1, 227, 1981.
74. 74. SEPLOWITZ, A.H., CHIEN, S., SMITH, F.R. Effects of lipoproteins on plasma viscosity. Atherosclerosis 38, 89, 1981.
75. 75. ANGELKORT, B., SPURK, P., GERLACH, A. et al. Significance of fibrinogen with regard to blood fluidity. Pharmacologial approaches for lowering fibrinogen. Clin Hemorheol 7, 277-286, 1987.